Aflac (AFL) to Release Earnings on Wednesday

Aflac (NYSE:AFL) is set to release its earnings data after the market closes on Wednesday, May 1st. Analysts expect Aflac to post earnings of $1.58 per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Aflac (NYSE:AFL) last issued its earnings results on Thursday, February 1st. The financial services provider reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.47 by ($0.22). The firm had revenue of $3.78 billion during the quarter, compared to analyst estimates of $4.44 billion. Aflac had a net margin of 24.92% and a return on equity of 17.59%. During the same period last year, the business earned $1.29 EPS. On average, analysts expect Aflac to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Aflac Stock Up 0.3 %

Shares of NYSE:AFL opened at $83.75 on Wednesday. The firm’s 50 day moving average price is $82.43 and its 200 day moving average price is $81.68. The stock has a market cap of $48.19 billion, a price-to-earnings ratio of 10.81, a price-to-earnings-growth ratio of 2.28 and a beta of 0.91. Aflac has a fifty-two week low of $64.10 and a fifty-two week high of $86.26. The company has a quick ratio of 0.06, a current ratio of 0.06 and a debt-to-equity ratio of 0.33.

Analyst Ratings Changes

AFL has been the topic of a number of research analyst reports. Raymond James raised their price objective on shares of Aflac from $83.00 to $88.00 and gave the stock an “outperform” rating in a report on Friday, February 2nd. Evercore ISI cut shares of Aflac from an “in-line” rating to an “underperform” rating and raised their price objective for the stock from $76.00 to $78.00 in a report on Thursday, January 4th. UBS Group raised their price objective on shares of Aflac from $80.00 to $84.00 and gave the stock a “neutral” rating in a report on Wednesday, January 10th. StockNews.com lowered shares of Aflac from a “hold” rating to a “sell” rating in a research report on Wednesday, April 10th. Finally, Keefe, Bruyette & Woods raised their target price on shares of Aflac from $83.00 to $87.00 and gave the stock a “market perform” rating in a research report on Wednesday, April 10th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Aflac currently has an average rating of “Hold” and a consensus price target of $82.15.

Insider Activity at Aflac

In other Aflac news, SVP Albert Riggieri sold 8,000 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $83.34, for a total transaction of $666,720.00. Following the sale, the senior vice president now directly owns 32,825 shares in the company, valued at approximately $2,735,635.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Aflac news, SVP Albert Riggieri sold 8,000 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $83.34, for a total transaction of $666,720.00. Following the sale, the senior vice president now directly owns 32,825 shares in the company, valued at approximately $2,735,635.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Arthur Reginald Collins sold 3,000 shares of the business’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $79.73, for a total transaction of $239,190.00. Following the sale, the director now owns 5,592 shares in the company, valued at $445,850.16. The disclosure for this sale can be found here. Insiders have sold a total of 46,493 shares of company stock worth $3,765,706 in the last three months. Insiders own 0.80% of the company’s stock.

About Aflac

Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates through Aflac Japan and Aflac U.S. segments. The Aflac Japan segment offers cancer, medical, nursing care, work leave, GIFT, and whole and term life insurance products, as well as WAYS and child endowment plans under saving type insurance products in Japan.